Hereditary factors in gynecologic cancer

Henry T. Lynch, Murray J. Casey, Trudy G. Shaw, Jane F. Lynch

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Cancer predisposition in some families is known to be the result of germ-line mutations. The most noteworthy hereditary gynecologic cancer syndromes include hereditary breast-ovarian cancer (HBOC) syndrome, wherein BRCA1 and BRCA2 germ-line mutations have been identified, and hereditary nonpolyposis colorectal cancer (HNPCC) of the Lynch syndrome II variant, wherein hMSH2, hMLH1, hPMS2, hMSH3, and hMSH6 germ-line mutations have been identified. DNA testing for specific cancer-associated germ-line mutations is now available for HBOC and HNPCC syndrome family members who are in the direct line of inheritance. Genetic counseling is mandatory prior to DNA testing and at the time of disclosure of findings. A patient found to be negative for the family's particular cancer-associated germ-line mutation can revert to general population screening recommendations. When a deleterious mutation is identified, the physician is able to predict a patient's lifetime susceptibility to breast and ovarian carcinomas in the HBOC syndrome or the cancers which characterize the Lynch syndrome II variant of HNPCC, particularly carcinomas of the colon, endometrium, and ovary. Management strategies can be offered which are designed to take advantage of the natural history of that distinct hereditary cancer syndrome. We discuss the unfolding developments concerning familial and heritable susceptibilities, molecular genetics, and possible carcinogenic co-factors of the three most common gynecologic cancers: carcinomas of the uterine cervix, endometrium, and ovary. We offer rationales for management based on current epidemiologic and clinical data and emerging technologies.

Original languageEnglish
Pages (from-to)319-338
Number of pages20
JournalOncologist
Volume3
Issue number5
StatePublished - 1998

Fingerprint

Germ-Line Mutation
Hereditary Nonpolyposis Colorectal Neoplasms
Lynch Syndrome II
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary Neoplastic Syndromes
Neoplasms
Ovary
Breast Neoplasms
DNA
Genetic Counseling
Disclosure
Endometrial Neoplasms
Endometrium
Uterine Cervical Neoplasms
Ovarian Neoplasms
Molecular Biology
Colon
Technology
Carcinoma
Physicians

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Hematology

Cite this

Lynch, H. T., Casey, M. J., Shaw, T. G., & Lynch, J. F. (1998). Hereditary factors in gynecologic cancer. Oncologist, 3(5), 319-338.

Hereditary factors in gynecologic cancer. / Lynch, Henry T.; Casey, Murray J.; Shaw, Trudy G.; Lynch, Jane F.

In: Oncologist, Vol. 3, No. 5, 1998, p. 319-338.

Research output: Contribution to journalArticle

Lynch, HT, Casey, MJ, Shaw, TG & Lynch, JF 1998, 'Hereditary factors in gynecologic cancer', Oncologist, vol. 3, no. 5, pp. 319-338.
Lynch, Henry T. ; Casey, Murray J. ; Shaw, Trudy G. ; Lynch, Jane F. / Hereditary factors in gynecologic cancer. In: Oncologist. 1998 ; Vol. 3, No. 5. pp. 319-338.
@article{4bbcfa0be09e498982ba94d7be5b9dca,
title = "Hereditary factors in gynecologic cancer",
abstract = "Cancer predisposition in some families is known to be the result of germ-line mutations. The most noteworthy hereditary gynecologic cancer syndromes include hereditary breast-ovarian cancer (HBOC) syndrome, wherein BRCA1 and BRCA2 germ-line mutations have been identified, and hereditary nonpolyposis colorectal cancer (HNPCC) of the Lynch syndrome II variant, wherein hMSH2, hMLH1, hPMS2, hMSH3, and hMSH6 germ-line mutations have been identified. DNA testing for specific cancer-associated germ-line mutations is now available for HBOC and HNPCC syndrome family members who are in the direct line of inheritance. Genetic counseling is mandatory prior to DNA testing and at the time of disclosure of findings. A patient found to be negative for the family's particular cancer-associated germ-line mutation can revert to general population screening recommendations. When a deleterious mutation is identified, the physician is able to predict a patient's lifetime susceptibility to breast and ovarian carcinomas in the HBOC syndrome or the cancers which characterize the Lynch syndrome II variant of HNPCC, particularly carcinomas of the colon, endometrium, and ovary. Management strategies can be offered which are designed to take advantage of the natural history of that distinct hereditary cancer syndrome. We discuss the unfolding developments concerning familial and heritable susceptibilities, molecular genetics, and possible carcinogenic co-factors of the three most common gynecologic cancers: carcinomas of the uterine cervix, endometrium, and ovary. We offer rationales for management based on current epidemiologic and clinical data and emerging technologies.",
author = "Lynch, {Henry T.} and Casey, {Murray J.} and Shaw, {Trudy G.} and Lynch, {Jane F.}",
year = "1998",
language = "English",
volume = "3",
pages = "319--338",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Hereditary factors in gynecologic cancer

AU - Lynch, Henry T.

AU - Casey, Murray J.

AU - Shaw, Trudy G.

AU - Lynch, Jane F.

PY - 1998

Y1 - 1998

N2 - Cancer predisposition in some families is known to be the result of germ-line mutations. The most noteworthy hereditary gynecologic cancer syndromes include hereditary breast-ovarian cancer (HBOC) syndrome, wherein BRCA1 and BRCA2 germ-line mutations have been identified, and hereditary nonpolyposis colorectal cancer (HNPCC) of the Lynch syndrome II variant, wherein hMSH2, hMLH1, hPMS2, hMSH3, and hMSH6 germ-line mutations have been identified. DNA testing for specific cancer-associated germ-line mutations is now available for HBOC and HNPCC syndrome family members who are in the direct line of inheritance. Genetic counseling is mandatory prior to DNA testing and at the time of disclosure of findings. A patient found to be negative for the family's particular cancer-associated germ-line mutation can revert to general population screening recommendations. When a deleterious mutation is identified, the physician is able to predict a patient's lifetime susceptibility to breast and ovarian carcinomas in the HBOC syndrome or the cancers which characterize the Lynch syndrome II variant of HNPCC, particularly carcinomas of the colon, endometrium, and ovary. Management strategies can be offered which are designed to take advantage of the natural history of that distinct hereditary cancer syndrome. We discuss the unfolding developments concerning familial and heritable susceptibilities, molecular genetics, and possible carcinogenic co-factors of the three most common gynecologic cancers: carcinomas of the uterine cervix, endometrium, and ovary. We offer rationales for management based on current epidemiologic and clinical data and emerging technologies.

AB - Cancer predisposition in some families is known to be the result of germ-line mutations. The most noteworthy hereditary gynecologic cancer syndromes include hereditary breast-ovarian cancer (HBOC) syndrome, wherein BRCA1 and BRCA2 germ-line mutations have been identified, and hereditary nonpolyposis colorectal cancer (HNPCC) of the Lynch syndrome II variant, wherein hMSH2, hMLH1, hPMS2, hMSH3, and hMSH6 germ-line mutations have been identified. DNA testing for specific cancer-associated germ-line mutations is now available for HBOC and HNPCC syndrome family members who are in the direct line of inheritance. Genetic counseling is mandatory prior to DNA testing and at the time of disclosure of findings. A patient found to be negative for the family's particular cancer-associated germ-line mutation can revert to general population screening recommendations. When a deleterious mutation is identified, the physician is able to predict a patient's lifetime susceptibility to breast and ovarian carcinomas in the HBOC syndrome or the cancers which characterize the Lynch syndrome II variant of HNPCC, particularly carcinomas of the colon, endometrium, and ovary. Management strategies can be offered which are designed to take advantage of the natural history of that distinct hereditary cancer syndrome. We discuss the unfolding developments concerning familial and heritable susceptibilities, molecular genetics, and possible carcinogenic co-factors of the three most common gynecologic cancers: carcinomas of the uterine cervix, endometrium, and ovary. We offer rationales for management based on current epidemiologic and clinical data and emerging technologies.

UR - http://www.scopus.com/inward/record.url?scp=0031787339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031787339&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 319

EP - 338

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -